Business
Cell MedX Corp. (CMXC) Arranges a Non-brokered Private Placement Financing
Cell MedX Corp. (CMXC) Arranges a Non-brokered Private Placement Financing.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arranged a non-brokered private placement offering (the “Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of $750,000.Each Unit sold under the Offering will consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant. Each Warrant will be exercisable into one share of the Company’s common stock at $0.20 per share.The Units will be issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act. The Units to U.S. Persons will be issued pursuant to the provisions of Rule 506(b) of Regulation D of the Act who qualify as “accredited investors” as that term is defined under Regulation D of the Act.The Company will use the proceeds from the Offering to fund its current business operations and to continue the development of its ebalance devices.The above does not constitute an offer to sell or a solicitation of an offer to buy any of Cell MedX’s securities in the United States. The securities have not been registered under the U.S. Securities Act and may not be offered or sold within the United States or to U.S. persons unless an exemption from such registration is available.About Cell MedX Corp. (OTCQB: CMXC) Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. The final report on the Observational Clinical Trials has been received by Health Canada. For more information about the Company and its technology please visit our website at www.cellmedx.com/investors/overview/. For the Company's newsletter please visit www.cellmedx.com/media/newsletters/ &...